Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute lymphoblastic leukemia
Pharma
Takeda's Iclusig wins first-line FDA nod to treat Ph+ALL
The FDA has approved Takeda's Iclusig for use plus chemotherapy for newly diagnosed, first-line patients with Philadelphia chromosome-positive ALL.
Kevin Dunleavy
Mar 19, 2024 3:22pm
Takeda's Iclusig tops Novartis' Gleevec decisively in Ph+ALL
Feb 14, 2023 5:00pm
ASH: Amgen's Blincyto looks to establish new leukemia standard
Dec 13, 2022 10:00am
Jazz secures FDA nod for revised blood cancer dosing schedule
Nov 22, 2022 10:30am
BioNTech, Astellas, Daiichi—Fierce Pharma Asia
Nov 18, 2022 10:11am
In Ph+ALL trial, Takeda's Iclusig outdoes Novartis' Gleevec
Nov 17, 2022 10:27am
